{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:06Z","timestamp":1758937206737,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.leukres.2021.106519","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T11:03:24Z","timestamp":1611918204000},"page":"106519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["IPS-3 Validation in 1012 cases with classical hodgkin lymphoma"],"prefix":"10.1016","volume":"102","author":[{"given":"Semra","family":"Paydas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahin","family":"La\u00e7in","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutlu","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Barista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birol","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsah","family":"Seydaoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuri","family":"Karadurmus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinem","family":"Civriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed Ali","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munci","family":"Yagci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emel","family":"Gurkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vehbi","family":"Ercolak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106519_bib0005","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s Disease. International prognostic factors Project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2021.106519_bib0010","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International prognostic score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2021.106519_bib0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the International Prognostic Score (IPS-7) and a simpler score (IPS-3) for advanced Hodgkin lymphoma in the modern era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2021.106519_bib0020","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106519_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial","volume":"161","author":"Evens","year":"2013","journal-title":"E2496. Br J Haem"},{"key":"10.1016\/j.leukres.2021.106519_bib0030","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3109\/10428194.2011.635861","article-title":"Stage IV anda ge over 45 are the only prognostic factors of the International Prognostic Score for advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series","volume":"53","author":"Guisado-Vasco","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2021.106519_bib0035","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2217\/bmm-2019-0303","article-title":"Systemic inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma","volume":"13","author":"Mirili","year":"2019","journal-title":"Biomark. Med."},{"key":"10.1016\/j.leukres.2021.106519_bib0040","article-title":"Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced stage classical Hodgkin lymphoma","author":"Kyrtsonias","year":"2020","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.leukres.2021.106519_bib0045","first-page":"336","volume":"178","author":"Guisado-Vasco","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.leukres.2021.106519_bib0050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdx373.024","article-title":"International Prognostic Scores (IPS7, IPS-3 and IPS-new) for predicition of FFS and OS in cases with Hodgkin Lymphoma. Which is more practical and accurate?","volume":"28","author":"Paydas","year":"2017","journal-title":"Ann Oncol Suppl"},{"key":"10.1016\/j.leukres.2021.106519_bib0055","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/annonc\/mdp337","article-title":"Stanford V program for locally advanced Hodgkin lymphoma: the memorial sloan-kttering Cancer center experience","volume":"21","author":"Edwards-Bennett","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2021.106519_bib0060","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.clml.2018.11.009","article-title":"Prognostic utility of the IPS3 Score for predicting outcomes in advanced Hodgkin lymphoma. Clin Lymphoma","volume":"19","author":"Ganesan","year":"2018","journal-title":"Myeloma & Leukemia"},{"key":"10.1016\/j.leukres.2021.106519_bib0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/A:1008325627670","article-title":"Is the International Prognostic Score for advanced Hodgkin\u2019s Disease applicable to early stage patients?","volume":"11","author":"Franklin","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2021.106519_bib0070","first-page":"122","article-title":"Validation of a simplified International Prognostic Score (IPS-3) in patients with advanced stage classical Hodgkin lymphoma","volume":"189","author":"Hayden","year":"2020","journal-title":"Blood Coagul. Fibrinolysis"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:20Z","timestamp":1758934820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":14,"alternative-id":["S0145212621000205"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106519","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IPS-3 Validation in 1012 cases with classical hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106519"}}